016580.KS
Whan In Pharm Co.,Ltd.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 10,390.00
−0.48%Year over year
Reported trailing growth
- Revenue
- +5.7%
- EBITDA
- -24.9%
- EBIT
- +57.3%
- EPS
- +5.2%
- Free cash flow
- +281.2%
- Operating cash flow
- +19.8%
Forward estimates
Based on analyst estimates
- Revenue
- -48.6%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +8.7%
- EBITDA
- -11.5%
- EBIT
- -24.1%
- Net income
- -17.2%
- EPS
- -18.2%
- Free cash flow
- +171.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026